Marty Chilberg
Long only, special situations, research analyst, healthcare

Sequenom 2013 Operating Results Review

Sequenom (SQNM) Points to Significant Expansion in Noninvasive Prenatal Testing (NIPT) Market

Sequenom released results for the quarter and year ended December 31st, 2013 on February 27th, 2014. The results were largely expected as revenues and cash burn had been preannounced. The 2013 10k and earnings conference call provided some clarity into the questions of primary importance to investors:

  1. Why is unit growth slowing for MaterniT21 and what does that say about the size of the market opportunity?
  2. How likely is achievement of the company goal to attain positive cash flow by the end of 2014?
  3. Will the company need to source new capital this year?

Cash flows

Sequenom reported net cash usage of $13.5m in December 2013....

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
FREESA PRO MEMBERS
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details